20 YEARS

SCRIP AWARDS 2024

WEDNESDAY 4 DECEMBER 2024 | RAFFLES LONDON AT THE OWO

EXAMPLE ENTRY FORM

BIOTECH COMPANY OF THE YEAR

ENTRY DEADLINE: FRIDAY 12 JULY, 2024

Biotech Company of the Year
Category Criteria

The biotech industry's entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies over the qualifying 12 months. The winner of the Biotech Company of the Year Award will be the firm that has achieved the most in the 12 months between 1 June 2022 - 30 June 2023. For example, this could be moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

Disclaimer: The companies, drugs, diseases and people in these entries are entirely fictional. Any resemblance to actual companies, drugs, diseases and persons living or dead is entirely coincidental.

CuttingEdge Biotech Inc's Entry For Biotech Company Of The Year

250-WORD (MAX) SUMMARY:

Boston, MA-based CuttingEdge Biotech Inc is developing next-generation respiratory and cardiovascular drugs based on the company's unique proprietary Bobinator technology platform. Its overall goal is to pioneer the discovery and development of a new generation of therapies for people with life-limiting rare lung and heart diseases.

CuttingEdge completed Phase II studies of its lead product, omelogibob, demonstrating proof of concept for the potential first-in-class logibobin inhibitor in Bevial's disease. The candidate was the subject of a multi-billion dollar licensing agreement for development and marketing with Grande Pharma plc which has already moved it into Phase III clinical trials.

Under the terms of the licensing agreement, CuttingEdge will receive $100m in upfront payments. The deal takes its lead investigational product, omelogibob forward to pivotal studies and gives CuttingEdge the funds to continue developing its earlier pipeline of anti-fibrotic agents from its proprietary Bobinator platform, including Phase I studies of CE-006 and CE-008.

Prior to the July multi-billion dollar licensing deal, CuttingEdge launched a follow-on public offering to raise a further $50m to support its early-stage research targeting the underlying pathophysiology of rare respiratory and lung diseases related to the logibobin and cardiobobin fibrotic pathways.

ENTRY (1,500 WORDS):

Name of entering company

CuttingEdge Biotech Inc

What has been the company's most significant achievement during the year?

Boston, MA-based CuttingEdge Biotech Inc is developing next-generation respiratory and cardiovascular drugs based on the Company's unique proprietary Bobinator technology platform.

CuttingEdge's scientific mission began and continues with the needs of patients, which fuels its vision of becoming a leading biotech in the respiratory and cardiovascular areas. Its overall goal is to pioneer the discovery and development of a new generation of therapies for people with life-limiting rare lung and heart diseases.

In July, CuttingEdge entered into its first multi-billion dollar deal with a big pharma company. The agreement with Grande Pharma plc was for the worldwide development and commercialization of CuttingEdge's clinical-stage, potential first-in-class oral inhibitor of logibobin, omelogibob, for Bevial's disease. The deal brought funds to CuttingEdge to allow it to focus on its earlier respiratory and cardiovascular rare disease pipeline.

Under the terms of the licensing agreement, CuttingEdge will receive $100m in upfront payments. CuttingEdge will also be eligible to receive up to an additional $1.5bn in clinical development, regulatory and commercial launch-related milestone payments, in addition to royalties in the range of low double-digit to mid-twenties percentage depending on the region.

Give details of what the firm has accomplished over the year in terms of:

- Bringing new products closer to their first markets

  In the qualifying 12 months, CuttingEdge completed Phase II studies of its lead product, omelogibob, demonstrating proof of concept for the potential first-in-class logibobin inhibitor in Bevial's disease. The candidate was the subject of a multibillion-dollar licensing agreement for development and marketing with Grande Pharma plc which has already moved it into Phase III clinical trials.

  In addition, CuttingEdge also progressed two preclinical candidates, CE-006 and CE-008, into Phase I clinical trials for the first time. The two candidates, also originated from its proprietary Bobinator platform, are targeting the underlying pathophysiology of rare respiratory and lung diseases related to the logibobin and cardiobobin fibrotic pathways.

- Raising funds

  Prior to the July multi-billion dollar licensing deal, CuttingEdge launched a follow-on public offering to raise a further $50m with the sale of 1.92 million shares at $25.00 each in December 2021. The proceeds will fund ongoing clinical development of CE-006 and CE-008 and support the progress of two other preclinical candidates which it plans to move into the clinic in the second quarter and further buildout of its Bobinator platform.

  The net proceeds from the offering will also be used for working capital and general corporate purposes.

- Signing significant licensing or partnership deals

  The most significant deal for CuttingEdgein the qualifying year was its the multibillion-dollar deal for with Grande Pharma plc for omelogibob for $100m in upfront payments, and up to an additional $1.5bn in clinical development, regulatory and commercial launch-related milestone payments, plus royalties (see above).

"We are proud that Grande Pharma, an expert in respiratory diseases with a legacy of bringing novel therapies to patients, recognized the potential of CuttingEdge's potential first-in-class logibobin inhibitor drug candidate, omelogibob" said Dr Fred Greatworth, CEO of CuttingEdge.

"Having brought omelogibob through to proof of concept, we are pleased that its Phase III development will benefit from Grande Pharma's experience and global organization, while we will continue to develop and expand our growing, innovative pipeline of small-molecule assets for rare respiratory and lung diseases related to the logibobin and cardiobobin fibrotic pathways."

- Showing strong management not afraid of making hard decisions

  Late last year, CuttingEdge Biotech took the decision to place on hold development of preclinical products from its other proprietary platform, Culinator, in order to conserve funds to support the early clinical studies of omelogibob and to complete preclinical testing of CE-006 and CE-008.

- Using proprietary science or technologies to address an unmet medical need

  CuttingEdge is using its proprietary Bobinator platform to transform the development of drugs for rare respiratory and cardiovascular diseases. The Bobinator platform has been used to discover intracellular factors affecting fibrosis in the heart and lungs that have never before been targeted for drug development.

  CuttingEdge's lead product, and the subject of its multi-billion dollar licensing deal with Grande Pharma, is omelogibob, a first-in-class oral inhibitor of logibobin, for the treatment of Bevial's disease. Logibobin sits at the apex of the logibobin cascade, part of the Bevial system in the lungs. It the first investigational drug designed to modulate this target and act on the underlying disease process in the hope of slowing the disease progression.

  Bevial's disease, a progressive and debilitating respiratory disorder. Patients' symptoms were alleviated with use of off-label treatments including antifibrotic therapies and bronchodilators to control exacerbations. The median survival time from diagnosis is five to eight years, and the five-year survival rate is approximately 70%.

  The firm's two other clinical candidates also originated from its proprietary Bobinator platform. They are also targeting the underlying pathophysiology of rare respiratory and lung diseases related to the logibobin and cardiobobin fibrotic pathways.

- Successfully transforming the business from an early stage to a more mature company

  The CuttingEdge team has transformed the firm in the qualifying 12 month period with its first multi-billion dollar licensing deal with a big pharma company. The deal takes its lead investigational product, omelogibob, forward to pivotal studies and gives CuttingEdge the funds to continue developing its earlier pipeline of anti-fibrotic agents from its Bobinator platform, including Phase I studies of CE-006 and CE-008.